Icometrix
AI-powered medical imaging analysis for neurological conditions.
- B2B
- saas
- subscription
- health
- enterprise software
- health platform
- biotechnology
- big data
- computer vision
- deep tech
- hardware
- machine learning
- artificial intelligence
- dt and ls
- biotechnology
- horizon europe
- spinout
- core ai
- ai applications
- eit ecosystem
- ai agents
- neurology
- eit health
- health it
- patient care
- ai drug discovery
- tech for hospitals and clinics
- tech for medical professionals
- techbio
- seal of excellence ec
- physician support tools
- hospital
- medical imaging
- techbio drug discovery
- clinical decision support
- ai for medical imaging
- biomarkers
- mri
- epilepsy
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £1.4m | Grant | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
icometrix is a health technology company founded in 2011 by Dirk Loeckx and Wim Van Hecke as a spin-off from the universities and university hospitals of Leuven and Antwerp, Belgium. The company specializes in developing artificial intelligence-driven software that analyzes brain MRI and CT scans to provide quantitative data for neurological conditions.
The firm's main product portfolio includes the FDA-cleared and CE-marked icobrain software, which assists clinicians in diagnosing and monitoring multiple sclerosis, dementia, Alzheimer's disease, traumatic brain injury (TBI), epilepsy, and stroke. Specific solutions include icobrain ms for multiple sclerosis, icobrain dm for dementia, and icobrain tbi for traumatic brain injuries. In November 2024, the company received FDA clearance for icobrain aria, an AI tool designed to detect and grade amyloid-related imaging abnormalities (ARIA), which are potential side effects of certain Alzheimer's therapies. Other solutions include icobrain ep for epilepsy and icolung, which was developed to measure lung involvement from chest CT scans during the COVID-19 pandemic.
icometrix operates on a business-to-business model, serving hospitals, imaging centers, pharmaceutical companies, and research institutions. Its technology is used in over 300 hospitals worldwide, and it collaborates with major pharmaceutical companies on clinical trials. The company has established strategic partnerships with major health and technology firms, including Philips, Siemens Healthineers, Aidoc, and the American College of Radiology, to integrate its AI solutions into existing clinical workflows and expand its market reach. Revenue is generated by providing its software solutions and analysis services. The company has raised a total of $20.2 million in funding, including a significant $18 million Series A round in 2019 led by Forestay Capital and Optum Ventures.
Keywords: medical imaging AI, neuroimaging, brain scan analysis, icobrain, neurological disorders, multiple sclerosis, Alzheimer's disease, traumatic brain injury, dementia, epilepsy, stroke, medical software, clinical decision support, quantitative MRI, AI diagnostics, digital health, FDA cleared AI, medical device software, radiology AI, imaging biomarkers